array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(99) "BMO Cuts Regeneron Price Target Following Eylea HD Struggles, Competitive Concerns By Investing.com" ["snippet_en"]=> string(85) "BMO Cuts Regeneron Price Target Following Eylea HD Struggles and Competition Concerns" ["url"]=> string(172) "https://fr.investing.com/news/company-news/bmo-reduit-lobjectif-de-cours-de-regeneron-suite-aux-difficultes-deylea-hd-et-aux-inquietudes-liees-a-la-concurrence-93CH-2626510" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-11-03" ["categories"]=> array(3) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(11) "Competition" [2]=> string(12) "Stock Market" } } [1]=> array(7) { ["title_en"]=> string(234) "Proprotein Convertase Subtilisin Kexin Type 9 Market Growth Trends Regional Analysis Segmentation Application Restraints Key Players Profile Forecast To By 2024-2031 | AFFiRiS AG, Sanofi and Regeneron Pharmaceuticals Inc, Novartis AG." ["snippet_en"]=> string(288) "Press release - DataM Intelligence 4Market Research - Proprotein Convertase Subtilisin Kexin Type 9 Market Growth Trends Regional Analysis Segmentation Application Restraints Key Players Profile Forecast To By 2024-2031 | AFFiRiS AG, Sanofi and Regeneron Pharmaceuticals Inc, Novartis AG." ["url"]=> string(95) "https://www.openpr.com/news/3704511/proprotein-convertase-subtilisin-kexin-type-9-market-growth" ["image_url"]=> string(78) "https://images.businessradar.com/articles/11fd18bc-bac2-48be-b414-3726fa784912" ["source"]=> string(10) "openpr.com" ["publication_date"]=> string(10) "2024-10-23" ["categories"]=> array(2) { [0]=> string(14) "Product Launch" [1]=> string(11) "Competition" } } [2]=> array(7) { ["title_en"]=> string(134) "Here's How Much $100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth Today - Regeneron Pharmaceuticals (NASDAQ:REGN)" ["snippet_en"]=> string(245) "Regeneron Pharmaceuticals REGN has outperformed the market over the past 15 years by 18.57% on an annualized basis producing an average annual return of 30.32%. Currently, Regeneron Pharmaceuticals has a market capitalization of $110.13 billion." ["url"]=> string(144) "https://www.benzinga.com/insights/news/24/10/41282200/heres-how-much-100-invested-in-regeneron-pharmaceuticals-15-years-ago-would-be-worth-today" ["image_url"]=> string(78) "https://images.businessradar.com/articles/501d5592-51ff-4619-aeb7-48f52ae42020" ["source"]=> string(12) "benzinga.com" ["publication_date"]=> string(10) "2024-10-12" ["categories"]=> array(3) { [0]=> string(9) "Valuation" [1]=> string(11) "Competition" [2]=> string(12) "Stock Market" } } [3]=> array(7) { ["title_en"]=> string(84) "Ebglyss FDA approval intensifies competition in atopic dermatitis market: GlobalData" ["snippet_en"]=> string(161) "Ebglyss' approval highlights the opportunity that exists in the AD space, and may have potential advantages in efficacy and safety against AD, GlobalData stated." ["url"]=> string(145) "https://www.financialexpress.com/business/healthcare-ebglyss-fda-approval-intensifies-competition-in-atopic-dermatitis-market-globaldata-3634412/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/dee87ea0-0a85-4319-bda0-5b11a55a0697" ["source"]=> string(20) "financialexpress.com" ["publication_date"]=> string(10) "2024-10-08" ["categories"]=> array(1) { [0]=> string(11) "Competition" } } [4]=> array(7) { ["title_en"]=> string(63) "Exploring Regeneron's Future: Innovations and Market Strategies" ["snippet_en"]=> string(147) "Discover the innovative strategies and market challenges faced by Regeneron Pharmaceuticals as it seeks to enhance growth and navigate competition." ["url"]=> string(98) "https://investorshangout.com/exploring-regenerons-future-innovations-and-market-strategies-46733-/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/5e6fb2c2-1996-4025-8d52-9513e6fe7118" ["source"]=> string(20) "investorshangout.com" ["publication_date"]=> string(10) "2024-09-30" ["categories"]=> array(4) { [0]=> string(11) "Competition" [1]=> string(15) "Market Movement" [2]=> string(21) "Competitive Behaviour" [3]=> string(5) "R & D" } } [5]=> array(7) { ["title_en"]=> string(65) "Regeneron, Sanofi blockbuster Dupixent wins FDA approval for COPD" ["snippet_en"]=> string(137) "Market analysts have estimated that the new COPD indication could bring in more than $1 billion in additional annual revenue for Dupixent" ["url"]=> string(101) "https://www.statnews.com/2024/09/27/regeneron-sanofi-blockbuster-dupixent-wins-fda-approval-for-copd/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/a27d8291-ba2b-4a43-a38b-d03ab2c84a2f" ["source"]=> string(12) "statnews.com" ["publication_date"]=> string(10) "2024-09-27" ["categories"]=> array(5) { [0]=> string(19) "New Revenue Streams" [1]=> string(5) "Award" [2]=> string(11) "Competition" [3]=> string(15) "Market Movement" [4]=> string(31) "Financial Update/Profit Warning" } } [6]=> array(7) { ["title_en"]=> string(79) "Students from Erbaa will represent Turkey in the Project Competition in America" ["snippet_en"]=> string(158) "High school students in Erbaa achieved great success by coming 3rd in Türkiye in the research projects competition held in the Technological Design category." ["url"]=> string(101) "https://www.kelkitgazetesi.com/erbaali-ogrencilerin-basarisi-amerikada-proje-yarismasina-katilacaklar" ["image_url"]=> NULL ["source"]=> string(18) "kelkitgazetesi.com" ["publication_date"]=> string(10) "2024-09-18" ["categories"]=> array(2) { [0]=> string(17) "Academic Research" [1]=> string(11) "Competition" } } [7]=> array(7) { ["title_en"]=> string(80) "MARTYR PROF. DR. INTERNATIONAL SUCCESS FROM İLHAN VARANK SCIENCE AND ART CENTER" ["snippet_en"]=> string(212) "Martyr Prof. Dr. Students of İlhan Varank Science and Art Center came third in the competition organized by TÜBİTAK and were entitled to represent our country in the international "Regeneron ISEF" competition." ["url"]=> string(141) "https://balikesirbirlikgazetesi.com/bilim-ve-teknoloji/sehit-prof-dr-ilhan-varank-bilim-ve-sanat-merkezi-nden-uluslararasi-basari-117997.html" ["image_url"]=> NULL ["source"]=> string(27) "balikesirbirlikgazetesi.com" ["publication_date"]=> string(10) "2024-09-13" ["categories"]=> array(4) { [0]=> string(17) "Academic Research" [1]=> string(11) "Competition" [2]=> string(21) "Competitive Behaviour" [3]=> string(5) "Event" } } [8]=> array(7) { ["title_en"]=> string(105) "3 stocks with very high potential (and risk): Intellia Therapeutics, ChargePoint Holdings, Blink Charging" ["snippet_en"]=> string(201) "Today we are going to look at 3 stocks that, in addition to trading below their price based on fundamentals, have a very high market target: Intellia Therapeutics, ChargePoint Holdings, Blink Charging." ["url"]=> string(126) "https://www.megabolsa.com/2024/08/13/potencial-elevadisimo-y-riesgo-intellia-therapeutics-chargepoint-holdings-blink-charging/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/078e63c3-985e-4f14-a898-a87855649101" ["source"]=> string(13) "megabolsa.com" ["publication_date"]=> string(10) "2024-08-13" ["categories"]=> array(5) { [0]=> string(11) "Competition" [1]=> string(15) "Market Movement" [2]=> string(12) "Stock Market" [3]=> string(13) "Collaboration" [4]=> string(14) "Product Launch" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc